Guide to Acute Coronary Syndrome (ACS) such STE-ACS (STEMI) and NSTE-ACS (NSTEMI) with Aspirin, P2Y12 Inhibitors, Unfractionated Heparin, Enoxaparin, Alteplase, Streptokinase (SK), and Nitroglycerin

---

Drug Dosing Table for ACS Management

Key Points:

• Aspirin is always administered first as a loading dose, followed by a daily maintenance dose for secondary prevention.
• Clopidogrel is preferred in fibrinolytic therapy, while ticagrelor or prasugrel is favored for PCI.
• Anticoagulation with UFH or enoxaparin is used depending on the reperfusion strategy and patient-specific factors such as renal function or age.
• Nitroglycerin can be used sublingually or intravenously for symptom control, depending on the severity of ischemia.
• Statins and ACE inhibitors are integral parts of long-term management to reduce recurrent cardiovascular events and stabilize atherosclerotic plaques.

This table simplifies medication selection and dosing for various ACS management scenarios, aligning with both international and regional practices (e.g., Thailand using 300 mg aspirin).

---

Introduction

Acute Coronary Syndrome (ACS) represents a spectrum of clinical conditions characterized by reduced blood flow to the heart muscle due to plaque rupture and thrombus formation within coronary arteries. ACS includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI), each requiring a nuanced approach to diagnosis and management.

This guide provides a complete overview of ACS diagnosis, medications, reperfusion therapies (PCI vs. fibrinolysis), and long-term management strategies tailored for advanced clinicians

---

1. Pathophysiology of ACS

The underlying mechanism of ACS is typically the rupture or erosion of an atherosclerotic plaque in a coronary artery, leading to thrombus formation and varying degrees of obstruction. This can result in:

• Complete occlusion, causing STEMI.
• Partial occlusion, which leads to NSTEMI or unstable angina.

Plaque rupture leads to platelet aggregation, thrombus formation, and myocardial ischemia or infarction depending on the severity of the obstruction.

---

2.1 Clinical Presentation

History Taking:

• Chest Pain: The hallmark symptom is retrosternal chest pain or discomfort, classically described as crushing, squeezing, or tight. Pain may radiate to the left arm, jaw, neck, or back and typically worsens with exertion.
• Associated Symptoms: Shortness of breath, nausea, diaphoresis, and a feeling of impending doom (angor animi) may accompany the chest pain.
• Risk Factors: History of smoking, diabetes, hypertension, dyslipidemia, obesity, and a family history of coronary artery disease (CAD).

Physical Examination:

• May reveal tachycardia, hypotension, diaphoresis, S3 or S4 gallop, or signs of heart failure (in severe cases).

ECG Findings:

• STEMI: Defined by ST-segment elevation in at least two contiguous leads, indicating full-thickness myocardial injury.
• NSTEMI/Unstable Angina: May present with ST-segment depression, T-wave inversion, or normal ECG findings.

Cardiac Biomarkers:

• Troponin I or T: The most sensitive and specific markers for myocardial infarction. Levels rise within 0-3-6 hours of myocardial injury, peak at 12-24 hours, and remain elevated for 7-14 days.
• hs-cTn I Levels if STEMI in EKG unnecessary to send hs-cTn I Levels any more
• CK-MB and Myoglobin: Can be used for early detection, but are less specific than troponins.

---

2.2 Alternative way use the ACS Spectrum:

1. Clinical Presentation:
   • Oligo/Asymptomatic: Patients might have minimal or no symptoms, potentially presenting with silent ischemia.
   • Increasing Chest Pain/Symptoms: Progression of chest pain, typically with exertion or stress, indicating worsening ischemia.
   • Persistent Chest Pain/Symptoms: Unremitting chest pain that suggests myocardial injury or infarction.
   • Cardiogenic Shock/Acute Heart Failure: Severe myocardial dysfunction resulting in poor cardiac output and hemodynamic instability.
   • Cardiac Arrest: Severe ACS can lead to lethal arrhythmias, resulting in sudden cardiac death or arrest.
2. ECG Findings:
   • Normal: Patients may present without significant ECG changes, often seen in unstable angina or low-risk NSTE-ACS.
   • ST Segment Depression: Typically seen in NSTEMI or unstable angina, reflecting subendocardial ischemia.
   • ST Segment Elevation: A hallmark of STEMI, indicating full-thickness myocardial infarction.
   • Malignant Arrhythmia: Life-threatening arrhythmias such as ventricular tachycardia or fibrillation, often associated with severe ischemia or infarction.
3. Working Diagnosis:
   • NSTE-ACS (Non-ST-elevation ACS): Includes both unstable angina and NSTEMI.
     • Unstable Angina: Presents with normal or non-elevated hs-cTn levels and no ST elevation on the ECG.
     • NSTEMI: Similar to unstable angina, but with elevated hs-cTn indicating myocardial injury.
   • STEMI (ST-elevation Myocardial Infarction): Defined by ST elevation on the ECG and elevated hs-cTn, representing full-thickness myocardial damage.
4. hs-cTn Levels:
   • Non-elevated: In unstable angina, troponin levels remain within normal limits despite symptoms.
   • Rise and Fall: In NSTEMI and STEMI, hs-cTn levels show a characteristic rise and fall, indicating myocardial necrosis.
5. Final Diagnosis:
   • Unstable Angina: Diagnosed when patients present with typical symptoms of ACS but have normal hs-cTn levels and no ST elevation.
   • NSTEMI: Characterized by elevated hs-cTn levels without ST elevation, indicating a non-transmural infarction.
   • STEMI: Diagnosed with both ST elevation and elevated hs-cTn levels, indicating significant myocardial damage.

This spectrum outlines the progression of ACS, from less severe conditions like unstable angina to life-threatening events such as STEMI and cardiac arrest. The ECG changes and troponin levels help in differentiating between these conditions, guiding immediate management strategies. The ultimate goal is timely revascularization (PCI or fibrinolysis) and secondary prevention to reduce future cardiovascular events.

---

3. Management Based on ACS Type

a) STEMI (ST-Elevation Myocardial Infarction)

Immediate Goal: Reperfusion therapy to restore blood flow through the affected coronary artery. This can be achieved through Primary PCI or fibrinolysis if PCI is unavailable.

Primary PCI (Percutaneous Coronary Intervention):

• Definition:
  • Primary PCI involves the use of a balloon catheter and stents to open the blocked artery mechanically. It is considered the gold standard in STEMI management because it directly restores blood flow, offers a high success rate, and lowers the risk of complications (e.g., recurrent ischemia, reinfarction, or stroke).
• Timing:
  • PCI should be performed within 90–120 minutes of the first medical contact to achieve optimal outcomes and minimize myocardial damage.
  • Delays beyond 120 minutes significantly reduce the benefits of PCI, which is why fibrinolysis may be indicated if PCI cannot be performed within this critical window.

Medications Before PCI:

• Aspirin:
  • Loading dose: 162-325 mg (Thailand commonly uses ASA grain V ~ 300 mg due to availability).
  • Maintenance dose: 81-100 mg daily indefinitely.
• P2Y12 Inhibitors:
  • Clopidogrel: 600 mg loading dose, followed by 75 mg daily.
  • Ticagrelor: 180 mg loading dose, followed by 90 mg twice daily.
  • Prasugrel: 60 mg loading dose, then 10 mg daily (contraindicated in patients ≥75 years, weight <60 kg, or history of stroke/TIA).
• Anticoagulation:
  • Unfractionated Heparin (UFH): Initial bolus of 60–70 U/kg (max 4000 U), followed by an infusion of 12–15 U/kg/hour.
  • Enoxaparin: 1 mg/kg subcutaneously every 12 hours.
  • Bivalirudin: Considered an alternative to UFH, particularly in patients at higher bleeding risk, but should be used with care.
• Glycoprotein IIb/IIIa Inhibitors 
  • Example: Abciximab, Eptifibatide, or Tirofiban, to be considered in patients with large thrombus burden, or persistent ischemia after initiation of antiplatelet therapy, but generally not routine.

Fibrinolysis (Thrombolysis):

• If Primary PCI cannot be performed within 120 minutes of the first medical contact, fibrinolysis should be initiated. In Thailand, streptokinase is commonly used due to its cost-effectiveness.
  • Fibrinolytic Agents:
    • Streptokinase:
      • Dose: 1.5 million units IV over 30-60 minutes.
      • Note: Streptokinase is widely used in Thailand due to its affordability compared to newer fibrinolytic agents.
    • Alteplase (tPA):
      • Dose: 15 mg IV bolus, followed by 0.75 mg/kg over 30 minutes, then 0.5 mg/kg over 60 minutes (max total dose 100 mg).
  • Antithrombotic Therapy During Fibrinolysis:
    • Aspirin:
      • Loading Dose: 162–325 mg (commonly, 300 mg).
      • Maintenance Dose: 81–100 mg daily indefinitely.
    • Clopidogrel:
      • Loading Dose:
        • 300 mg for patients ≤75 years.
        • 75 mg daily for patients >75 years (without a loading dose).
      • Maintenance Dose: 75 mg daily.
    • Anticoagulation:
      • Continue anticoagulation for at least 48 hours (up to 8 days or until revascularization is performed):
        • Unfractionated Heparin (UFH): Bolus of 60 U/kg (max 4000 U), followed by an infusion of 12 U/kg/hour.
        • Enoxaparin: 1 mg/kg subcutaneously every 12 hours.
        • Fondaparinux: 2.5 mg subcutaneously daily as an alternative, but it requires UFH supplementation during PCI to prevent catheter thrombosis.
  • PCI Timing After Fibrinolysis:
    • Rescue PCI:
      • Immediate PCI is indicated if there are signs of failed reperfusion following fibrinolysis. This includes:
        • Persistent chest pain.
        • ST-segment elevation that continues 60–90 minutes after fibrinolytic therapy.
        • Hemodynamic instability or worsening heart failure.
      • Rescue PCI is an emergency procedure and should be performed as soon as possible after identifying failed fibrinolysis.
    • Routine PCI (Pharmacoinvasive Strategy):
      • If fibrinolysis is successful, PCI can be performed on a delayed but urgent basis to further stabilize the patient and improve long-term outcomes. The recommended timing for this is typically:
        • Within 3–24 hours after successful fibrinolysis, known as pharmacoinvasive PCI.
        • Performing PCI within this time frame reduces the risk of re-occlusion of the infarct-related artery and improves outcomes.
      • Studies suggest that early routine PCI (within this window) improves outcomes compared to waiting longer or performing PCI only if recurrent ischemia occurs.
    • Elective PCI:
      • If there is no immediate risk or recurrent ischemic symptoms after fibrinolysis, PCI may be deferred beyond the 24-hour window, but it should generally be performed within the first week post-event to optimize revascularization outcomes.
    • Key Points:
      • Rescue PCI should be performed immediately in the case of fibrinolysis failure.
      • Routine PCI should ideally be performed within 3-24 hours of successful fibrinolysis.
      • Delaying PCI beyond 24 hours may be considered in specific cases without recurrent symptoms, but the general guideline is to perform it within the first week to ensure optimal recovery and prevention of further ischemic events.

b) NSTEMI/Unstable Angina

Goal: Risk stratification and appropriate medical therapy or early invasive strategy.

• Medications:
  • Aspirin:
    • Loading Dose: 162-325 mg (or ASA grain V ~ 300 mg in Thailand).
    • Maintenance Dose: 81-100 mg daily indefinitely.
  • P2Y12 Inhibitors (Dual Antiplatelet Therapy - DAPT):
    • Clopidogrel: 300-600 mg loading dose, followed by 75 mg daily.
    • Ticagrelor: 180 mg loading dose, followed by 90 mg twice daily.
      • Note: Prasugrel is not recommended in NSTEMI unless coronary anatomy is known, and PCI is planned due to increased bleeding risk.
  • Anticoagulation:
    • Enoxaparin: 1 mg/kg subcutaneously every 12 hours.
    • Unfractionated Heparin (UFH): 60 U/kg bolus, followed by 12 U/kg/hour infusion.
    • Fondaparinux: 2.5 mg subcutaneously daily, particularly in patients at high bleeding risk.
      • Note: If Fondaparinux is used and the patient undergoes PCI, an additional bolus of UFH should be given during the procedure to prevent catheter thrombosis.
  • Invasive Strategy:
    • Risk Stratification: Based on the patient's clinical presentation, ECG changes, and elevated biomarkers (e.g., troponins), patients can be categorized into low-risk or high-risk groups. The following patients are considered high-risk:
      • Persistent or recurrent ischemic symptoms.
      • Dynamic ST or T-wave changes on ECG.
      • Hemodynamic instability (e.g., hypotension, heart failure).
      • Positive biomarkers (elevated troponin).
      • Major arrhythmias or sustained ventricular tachycardia.
    • Timing:
      • For high-risk patients, perform early coronary angiography (within 24–48 hours) followed by either PCI or Coronary Artery Bypass Grafting (CABG), depending on coronary anatomy.

---

4. Strategies to Reduce Bleeding Risk During PCI:

1. Anticoagulant Dosing:
   • Adjust anticoagulant doses based on body weight and kidney function, especially in women and older adults, to avoid excessive anticoagulation.
2. Radial Artery Access:
   • Use the radial artery instead of the femoral artery for PCI to lower the risk of bleeding and vascular complications.
3. Proton Pump Inhibitors (PPIs):
   • Prescribe PPIs for patients on DAPT who have a high risk of gastrointestinal bleeding, such as those with:
     • History of GI ulcers or bleeding.
     • Taking anticoagulants, NSAIDs, or corticosteroids.
   • Consider PPIs for patients with 2 or more risk factors like:
     • Age ≥65, dyspepsia, GERD, Helicobacter pylori, or chronic alcohol use.
4. Oral Anticoagulants (OAC):
   • With VKAs (e.g., Warfarin): Continue PCI without stopping VKA if INR <2.5. Avoid additional UFH if INR >2.5.
   • With NOACs: Regardless of the last NOAC dose, add low-dose anticoagulation:
     • Enoxaparin: 0.5 mg/kg IV, or
     • UFH: 60 IU/kg IV.
5. Antiplatelet Therapy:
   • Use aspirin during PCI, but avoid pre-treatment with P2Y12 inhibitors (e.g., clopidogrel, ticagrelor) to reduce bleeding risk.
6. Glycoprotein IIb/IIIa Inhibitors:
   • Reserve for bailout situations or when there are peri-procedural complications.

---

5. Coronary Artery Bypass Grafting (CABG)

Indications for CABG:

• Multivessel disease (especially involving the left main coronary artery).
• Failed PCI or anatomy unsuitable for PCI.
• In some NSTEMI cases with complex coronary anatomy.

Medications Before and After CABG:

• Before CABG: Continue aspirin; discontinue P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) 5-7 days before elective CABG.
• After CABG: Restart dual antiplatelet therapy (DAPT), continue beta-blockers, ACE inhibitors, and statins.

---

6. Post-PCI In-Hospital Care

After a Percutaneous Coronary Intervention (PCI), patient management focuses on optimizing medication therapy, monitoring for complications, and ensuring smooth recovery before discharge. Here are the key components of in-hospital care following PCI:

6.1. Immediate Post-Procedure Monitoring:

• Vital Signs: Continuous monitoring of heart rate, blood pressure, and oxygen saturation to detect any signs of hemodynamic instability or complications.
• Access Site Care:
  • For radial artery access: Monitor for bleeding, hematoma, or radial artery occlusion.
  • For femoral artery access: Monitor for bleeding, pseudoaneurysm, or arteriovenous fistula.
• Electrocardiogram (ECG) Monitoring: Routine ECG to detect any early signs of arrhythmias or recurrent ischemia.
• Hemoglobin and Hematocrit Monitoring: Assess for post-procedural bleeding complications, especially if the patient exhibits signs of anemia.

6.2. Medication Adjustments Post-PCI:

a) Antiplatelet Therapy:

• Dual Antiplatelet Therapy (DAPT):
  • Continue aspirin 81–100 mg daily indefinitely.
  • Initiate or continue P2Y12 inhibitor (prasugrel, ticagrelor, or clopidogrel):
    • Ticagrelor: 180 mg loading dose, followed by 90 mg twice daily.
    • Prasugrel: 60 mg loading dose, followed by 10 mg daily (contraindicated in patients ≥75 years, weight <60 kg, or history of stroke/TIA).
    • Clopidogrel: 600 mg loading dose, followed by 75 mg daily (for patients who cannot tolerate ticagrelor or prasugrel).

b) Anticoagulation:

• Unfractionated Heparin (UFH) or bivalirudin is generally discontinued post-PCI unless there is an indication for long-term anticoagulation (e.g., atrial fibrillation, mechanical valves).
• Enoxaparin: For select patients requiring ongoing anticoagulation, continue at 1 mg/kg SC every 12 hours, with dose adjustments for renal impairment.

c) Statin Therapy:

• High-intensity statins (e.g., atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily) should be continued or initiated in all patients post-PCI to reduce the risk of recurrent cardiovascular events and to stabilize atherosclerotic plaques.
  • Target LDL <70 mg/dL or ≥50% reduction from baseline.

d) Beta-Blockers:

• Continue or initiate beta-blockers (e.g., metoprolol, carvedilol) for patients with left ventricular dysfunction, heart failure, or to manage hypertension and heart rate post-PCI.

e) ACE Inhibitors / ARBs:

• Initiate or titrate ACE inhibitors (e.g., lisinopril) or ARBs for patients with:
  • Left ventricular dysfunction (LVEF <40%).
  • Hypertension.
  • Diabetes or heart failure to prevent adverse cardiac remodeling.

f) Proton Pump Inhibitors (PPIs):

• Consider PPIs (e.g., omeprazole) in patients on DAPT who are at high risk of gastrointestinal bleeding, especially if they have a history of ulcers or concurrent NSAID use.

6.3. Monitor for Complications:

a) Bleeding:

• Assess for bleeding complications at the access site, gastrointestinal bleeding, or retroperitoneal bleeding (especially with femoral access).

b) Arrhythmias:

• Continuous telemetry monitoring is recommended, particularly in the first 24-48 hours post-PCI to detect atrial fibrillation, ventricular arrhythmias, or conduction blocks.

c) Acute Kidney Injury (AKI):

• Monitor renal function (serum creatinine, urine output) post-PCI, especially in patients with pre-existing kidney disease or those who received a large volume of contrast dye.

6.4. Early Mobilization and Rehabilitation:

• Early Mobilization: Encourage patients with radial access to mobilize early (typically within a few hours), while those with femoral access may require a longer period of bed rest (usually 4-6 hours).
• Cardiac Rehabilitation: Initiate discussions about cardiac rehabilitation programs before discharge to promote long-term recovery through structured exercise, education, and lifestyle modification.

---

7. Absolute and Relative Contraindications to Fibrinolysis

Absolute Contraindications:

• History of intracranial hemorrhage.
• Known structural cerebral vascular lesion or malignant intracranial neoplasm.
• Ischemic stroke within the past 3 months (except acute stroke within 4.5 hours).
• Suspected aortic dissection.
• Active bleeding or bleeding diathesis.
• Significant closed-head or facial trauma within 3 months.
• Intracranial or intraspinal surgery within 2 months.
• Severe uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg).

Relative Contraindications:

• History of chronic, poorly controlled hypertension.
• Traumatic or prolonged CPR (>10 minutes).
• Recent internal bleeding (within 2-4 weeks).
• Pregnancy, peptic ulcer, or advanced age (>75 years).
• Anticoagulation therapy with elevated INR.

---

8. ISAR-REACT 5 Trial: Ticagrelor vs. Prasugrel

The ISAR-REACT 5 trial compared ticagrelor and prasugrel in patients with ACS. Key findings include:

• Prasugrel was found to be superior to ticagrelor in reducing combined outcomes of death, myocardial infarction, and stroke.
• Prasugrel was associated with a lower risk of recurrent MI, though ticagrelor is preferred in patients ≥75 years, low body weight, or with a history of stroke/TIA due to a better safety profile regarding bleeding.

• Prasugrel

  • Recommended for:
    • Patients under 75 years old: Studies showed better outcomes with prasugrel in younger patients without significant safety concerns.
    • Patients without a history of stroke or transient ischemic attack (TIA): Prasugrel is contraindicated in those with a history of stroke or TIA because of the higher risk of intracranial bleeding.
    • Patients with a body weight above 60 kg (132 lbs): Prasugrel is safer for patients with a higher body weight because they have a lower risk of bleeding.
    • Lower bleeding risk: Overall, prasugrel has a lower incidence of bleeding in patients who meet the above criteria.

• Ticagrelor

  • Recommended for:
    • Patients aged ≥75 years: Due to the increased risk of bleeding with prasugrel in older adults, ticagrelor is preferred.
    • Patients with a history of stroke or TIA: Ticagrelor is the safer option for patients with a cerebrovascular disease history.
    • Patients with a body weight under 60 kg: Ticagrelor is preferred in individuals with lower body weight due to the increased bleeding risk associated with prasugrel in this group.
    • Patients at high bleeding risk: Ticagrelor is typically chosen for patients at high risk of bleeding due to its more favorable safety profile regarding bleeding complications.

  • Numerical Risk Differences

  • The trial found a 15% relative reduction in the primary endpoint (composite of death, MI, or stroke) in favor of prasugrel over ticagrelor.
  • Ticagrelor had a significantly higher incidence of major bleeding in certain subgroups, necessitating careful patient selection, especially in older and lighter patients.

---

9. Discharge Timing

STEMI Discharge Timing:

1. Primary PCI within 2 hours: Immediate reperfusion is key. After successful PCI and no complications, low-risk STEMI patients can be discharged early, sometimes within 24 hours.
2. 48-hour CCU stay: Most STEMI patients are monitored in the CCU for 48 hours, especially those with:
   • Heart failure.
   • Malignant arrhythmias (e.g., VT, VF).
   • Anterior wall MI (high-risk infarcts).
3. Early Discharge (24 hours):
   • No heart failure (normal echocardiogram).
   • No malignant arrhythmias.
   • Non-anterior MI (e.g., inferior MI).

NSTEMI Discharge Timing:

1. CAG within 24 hours: Urgent coronary angiography is done within 24 hours to assess the coronary anatomy, followed by PCI if needed.
2. Echocardiogram first: To check LV function, rule out complications, and confirm no heart failure.
3. Discharge in 48-72 hours: If low-risk, with normal echo and successful PCI, NSTEMI patients can be discharged within 48-72 hours post-procedure. High-risk patients may need longer monitoring.

---

10. Secondary Prevention After ACS (A, B, C, D, E Approach)

Secondary prevention after ACS aims to reduce the risk of recurrent cardiovascular events and promote overall health. Here’s how the ABCDE approach applies in this context:

• A - Antiplatelet Therapy / Assess Risk
  • Antiplatelet Therapy (DAPT):
    • Aspirin: 81-100 mg daily indefinitely.
    • P2Y12 Inhibitor: Continue for at least 12 months after ACS. Options include:
      • Ticagrelor: 90 mg twice daily.
      • Prasugrel: 10 mg daily (contraindicated in patients ≥75 years, weight <60 kg, or history of stroke/TIA).
      • Clopidogrel: 75 mg daily (for those with contraindications to ticagrelor or prasugrel).
    • Risk Stratification: Assess bleeding risk and consider modifying DAPT duration (e.g., shortened DAPT for high bleeding risk or extended DAPT for high ischemic risk).
• B - Blood Pressure Management
  • Target: Maintain BP <130/80 mm Hg.
  • Medications:
    • ACE inhibitors (e.g., lisinopril) or ARBs for patients with hypertension or reduced ejection fraction.
    • Beta-blockers for long-term control of heart rate, blood pressure, and ischemic symptoms (especially if there is heart failure or reduced LVEF).
    • MRAs (Mineralocorticoid Receptor Antagonists) for patients with heart failure or diabetes post-ACS.
• C - Cholesterol Control
  • High-intensity statin therapy:
    • Atorvastatin 40-80 mg daily or Rosuvastatin 20-40 mg daily to achieve LDL <70 mg/dL or a ≥50% reduction from baseline.
    • Consider adding ezetimibe or a PCSK9 inhibitor if LDL goals are not met with statins alone.
  • Cholesterol Monitoring: Regular follow-up to assess cholesterol levels and adjust therapy as needed.
• D - Diabetes / Diet and Weight Management
  • Diabetes Management:
    • Metformin is the first-line therapy for diabetes control.
    • Consider SGLT2 inhibitors or GLP-1 receptor agonists for cardiovascular benefit in patients with type 2 diabetes.
  • Diet and Weight Management:
    • Emphasize a heart-healthy diet rich in vegetables, fruits, nuts, legumes, fish, and whole grains.
    • Promote weight loss if overweight or obese and encourage regular physical activity.
• E - Exercise / Smoking Cessation
  • Exercise:
    • Encourage ≥150 minutes per week of moderate-intensity aerobic exercise or 75 minutes per week of vigorous-intensity exercise.
    • Promote participation in cardiac rehabilitation programs post-ACS.
  • Smoking Cessation:
    • Pharmacotherapy (e.g., nicotine replacement therapy, varenicline, bupropion) combined with behavioral interventions to maximize quit rates.
    • Continuous support for smoking cessation in follow-up visits.

---

Conclusion:

This detailed overview outlines the clinical presentation, diagnosis, and management strategies across the ACS spectrum. From initial assessment to long-term secondary prevention, the aim is to reduce myocardial damage, prevent complications, and lower the risk of recurrent cardiovascular events through timely intervention, including PCI, fibrinolysis, or CABG. Risk stratification, medication optimization, and careful consideration of contraindications to fibrinolysis ensure effective and safe care in ACS management